


 Substitute Form PTO-1449
 (Modified)

 U.S. Department of Commerce
 Patent and Trademark Office

 Attorney's Docket No.
 20750-034US1

 Application No.
 10/540,650

**Information Disclosure Statement
 by Applicant**

(Use several sheets if necessary)

 Applicant
 Bradley Teegarden, et al.

 Filing Date
 April 21, 2006

Group Art Unit

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	A1	US 3939271	02/17/1976	Gschwend			
	A2	US 4022800	05/10/1997	Gschwend			
	A3	US 4099012	07/04/1978	Gschwend			
	A4	US 4405644	09/20/1983	Kabbe <i>et al.</i>			
	A5	US 4409231	10/11/1983	Stenzel <i>et al.</i>			
	A6	US 4985352	01/15/1991	Julius <i>et al.</i>			
	A7	US 5077409	12/31/1991	Wissner			
	A8	US 5128351	07/07/1992	Wissner			
	A9	US 5523280	06/04/1996	Chene <i>et al.</i>			
	A10	US 5663388	05/27/1997	Diana <i>et al.</i>			
	A11	US 5661024	08/26/1997	Kao <i>et al.</i>			
	A12	US 5739153	04/14/1998	Peignier <i>et al.</i>			
	A13	US 5856514	01/05/1999	Peignier <i>et al.</i>			
	A14	US 5886044	03/23/1999	Widdowson <i>et al.</i>			
	A15	US 5905080	05/18/1999	Duckworth <i>et al.</i>			
	A16	US 5945382	08/31/1999	Cantegril <i>et al.</i>			
	A17	US 5990133	11/23/1999	Gaster <i>et al.</i>			
	A18	US 6005008	12/21/1999	Widdowson <i>et al.</i>			
	A19	US 6028085	02/22/2000	Bromibge			
	A20	US 6037377	03/14/2000	Anderskewitz <i>et al.</i>			
	A21	US 6054472	04/25/2000	Armistead <i>et al.</i>			
	A22	US 6140509	10/31/2000	Behan <i>et al.</i>			
	A23	US 6271261	08/07/2001	Widdowson			
	A24	US 6297261	10/02/2001	Christophersen <i>et al.</i>			
	A25	US 6417393	07/09/2002	Christophersen <i>et al.</i>			
	A26	US 6479480	11/12/2002	Moyes <i>et al.</i>			
	A27	US 6479519	11/12/2001	Astles <i>et al.</i>			

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-034US1	Application No. 10/540,650
	Applicant Bradley Teegarden, et al.		
	Filing Date April 21, 2006	Group Art Unit	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	A28	US 6531291	03/11/2003	Kabbash <i>et al.</i>			
	A29	US 6541209	04/01/2003	Behan <i>et al.</i>			
	A30	US 6696475	02/24/2004	Dahl <i>et al.</i>			
	A31	US 6706749	03/16/2004	Dahl <i>et al.</i>			
	A32	US 2004/0102636	05/27/2004	Miller <i>et al.</i>			
	A33	US 6784183	08/31/2004	Lavielle <i>et al.</i>			
	A34	US 2005/0054691	03/10/2005	Potter <i>et al.</i>			
	A35	US 2005/0267097	12/01/2005	Pinto <i>et al.</i>			
	A36	US 2006/0014705	01/19/2006	Howitz <i>et al.</i>			
	A37	US 2006/0205792	09/14/2006	Wong <i>et al.</i>			
	A38	US 2007/0037827	02/15/2007	Nunes <i>et al.</i>			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclasses	Translation	
							Yes	No
	A39	DE 4203201	08/12/1993	Germany			Abstract	
	A40	EP 0405602	01/02/1991	Europe				
	A41	EP 0410552	01/30/1991	Europe			Abstract	
	A42	EP 0538156	04/21/1993	Europe			Abstract	
	A43	EP 1108720	06/20/2001	Europe				
	A44	EP 1558582	08/03/2005	Europe				
	A45	EP 1734039	12/20/2006	Europe				
	A46	FR 2705962	12/09/1994	France			In US 5,739,153	
	A47	JP 0393774	04/18/1991	Japan			Abstract	
	A48	JP 07165724	06/27/1995	Japan			Abstract	
	A49	JP 09227524	09/02/1997	Japan			Abstract	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-034US1	Application No. 10/540,650
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Bradley Teegarden, et al.	
		Filing Date April 21, 2006	Group Art Unit

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	A50	WO 93/16036	08/19/1993	WIPO			In US 6,037,377	
	A51	WO 93/22287	11/11/1993	WIPO			In US 5,856,514	
	A52	WO 94/29276	12/22/1994	WIPO			In US 5,739,153	
	A53	WO 96/02138	02/01/1996	WIPO			w/English translation	
	A54	WO 96/10559	04/11/1996	WIPO				
	A55	WO 97/04772	02/13/1997	WIPO				
	A56	WO 97/03967	02/06/1997	WIPO				
	A57	WO 97/04773	02/13/1997	WIPO				
	A58	WO 97/29748	08/21/1997	WIPO				
	A59	WO 97/34881	09/25/1997	WIPO				
	A60	WO 97/45111	12/04/1997	WIPO				
	A61	WO 98/24785	06/11/1998	WIPO				
	A62	WO 99/06354	02/11/1999	WIPO				
	A63	WO 99/32436	07/01/1999	WIPO				
	A64	WO 99/32463	07/01/1999	WIPO				
	A65	WO 99/52927	10/21/1999	WIPO				
	A66	WO 00/57877	10/05/2000	WIPO				
	A67	WO 00/64866	11/02/2000	WIPO				
	A68	WO 00/66562	11/09/2000	WIPO				
	A69	WO 01/21160	03/29/2001	WIPO				
	A70	WO 01/29008	04/26/2001	WIPO				
	A71	WO 02/39987	05/23/2002	WIPO				
	A72	WO 02/076464	10/03/2002	WIPO				
	A73	WO 03/062206	07/31/2003	WIPO				
	A74	WO 2004/028450	04/08/2004	WIPO				
	A75	WO 2004/058722	07/15/2004	WIPO				

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-034US1	Application No. 10/540,650
	Applicant Bradley Teegarden, et al.		
	Filing Date April 21, 2006	Group Art Unit	

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclasses	Translation	
							Yes	No
	A76	WO 2004/071426	08/26/2004	WIPO				
	A77	WO 2004/085433	10/07/2004	WIPO				
	A78	WO 2004/096771	11/11/2004	WIPO				
	A79	WO 2005/012254	02/10/2005	WIPO				
	A80	WO 2005/077345	08/25/2005	WIPO				
	A81	WO 2005/103011	11/03/2005	WIPO				
	A82	WO 2006/018662	02/23/2006	WIPO				
	A83	WO 2006/049941	05/11/2006	WIPO				
	A84	WO 2006/060654	06/08/2006	WIPO				
	A85	WO 2006/076592	07/20/2006	WIPO				
	A86	WO 2006/081335	08/03/2006	WIPO				
	A87	WO 2006/089871	08/31/2006	WIPO				
	A88	WO 2007/002559	01/04/2007	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	A89	American Academy of Sleep Medicine, "The International Classification of Sleep Disorders, Revised," 2001
	A90	Andrezejewska-Buczko, J. et al., "Serotonin in diabetic retinopathy," <i>Klinika Oczna</i> , 98(2):101-4 (1996) ABSTRACT*
	A91	Berge, S. et al., "Pharmaceutical salts," <i>Journal of Pharmaceutical Sciences</i> , 66(1):1-19 (1977)
	A92	Blier, P. et al., "Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain," <i>Journal of Psychiatry and Neuroscience</i> , 26(1):37-43 (2000)
	A93	Cameron, N. et al., "The effects of 5-hydroxytryptamine 5-HT ₂ receptor antagonists on nerve conduction velocity and endoneurial perfusion in diabetic rats," <i>Naunyn Schmiedeberg's Archive of Pharmacology</i> , 367:607-14 (2003)
	A94	Casey, C. et al., "Constitutively active mutant 5HT _{2A} serotonin receptors: inverse agonist activity of classical 5HT _{2A} antagonists," <i>Society for Neuroscience</i> , 22:1778 (1996) ABSTRACT
	A95	Cazzola, M. et al., "5-HT modifiers as a potential treatment of asthma," <i>TiPS</i> , 21:13-6 (2000)
	A96	Chang, F. A. et al., "Mechanism of ocular hypotensive action of ketanserin," <i>Journal of Ocular Pharmacology</i> , 1(2):137-47 (1985)
	A97	Cohen-Mansfield, J. et al., "Agitated behaviors in the elderly I. a conceptual review," <i>JAGS</i> , 34(10):711-21 (1986)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-034US1	Application No. 10/540,650
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Bradley Teegarden, et al.	
		Filing Date April 21, 2006	Group Art Unit
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	A98	Collier, T. L. et al., "Radiosynthesis and in vivo evaluation of the psuedopeptide δ -opioid antagonist [125 I]-ITIPP(ψ)," <i>Journal of Labelled Cpd. Radiopharm.</i> , 42 (Suppl. 1):S264-6 (1999)
	A99	De Bie, J. J. et al., "Modulation of airway hyperresponsiveness and eosinophilia by selective histamine and 5-HT receptor antagonists in a mouse model of allergic asthma," <i>British Journal of Pharmacology</i> , 124:857-64 (1998)
	A100	Dosa, P.I. et al., "Synthesis and SAR of solubilized pyrazole derivatives as 5-HT _{2A} inverse-agonists for platelet aggregation," 232 th ACS National Meeting, Medi 431
	A101	Elphick, G. et al., "The human polyomavirus, JCV, uses serotonin to infect cells," <i>Science</i> , 306:1380-3 (2004)
	A102	Gründer, G. et al., "Time course of 5-HT _{2A} receptor occupancy in the human brain after a single dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography," <i>Neuropsychopharmacology</i> , 17(3):175-85 (1997)
	A103	Herrick-Davis, K. et al., "Constitutively active 5HT _{2C} serotonin receptor created by site directed mutagenesis," <i>Society for Neuroscience</i> , 22:1779 (1996) ABSTRACT
	A104	Herrick-Davis, K. et al., "Activating mutations of the serotonin 5HT _{2c} receptor," <i>Journal of Neurochemistry</i> , 69(3):1138-44 (1997)
	A105	Kanayama, M. et al., "New treatment of lumbar disc herniation using 5-hydroxytryptamine _{2A} receptor inhibitor: a randomized controlled trial," <i>Journal of Neurosurgery: Spine</i> , 2:441-6 (2005)
	A106	Katz, I. et al., "Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized double-blind trial," <i>Journal of Clinical Psychiatry</i> , 60(2): 107-15 (1999)
	A107	Koss, E. et al., "Assessing patterns of agitation in Alzheimer's disease patients with the Cohen-Mansfield agitation inventory," <i>Alzheimer's Disease and Associated Disorders</i> , 11(S2):S45-50 (1997)
	A108	Landolt, H. et al., "Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra," <i>Neuropsychopharmacology</i> , 21(3):455-66 (1999)
	A109	Le Bas, M. et al., "Radioiodinated analogs of EP 00652218 for the exploration of the tachykinin NK1 receptor by spect," <i>Journal of Labelled Cpd. Radiopharm.</i> , 44(S1):S280-2 (2001)
	A110	Mastropasqua, L. et al., "Ocular hypertensive effect of ketanserin in patients with primary open angle glaucoma," <i>Acta Ophthalmologica Scandinavica</i> , 75:24-5 (1997)
	A111	Muto, T. et al., "Protective effects of sarpogrelate, a 5HT _{2A} antagonist, against postischemic myocardial dysfunction in guinea-pig hearts," <i>Molecular and Cellular Biochemistry</i> , 272:119-32 (2005)
	A112	National Institutes of Health, "Facts about Insomnia," NIH publication no. 95-3801 (1995)
	A113	Nishiyama, T., "Effects of 5HT _{2A} receptor antagonist, sarpogrelate on thermal or inflammatory pain," <i>European Journal of Pharmacology</i> , 516:18-22 (2005)
	A114	Nomura, S. et al., "5HT _{2A} receptor antagonist increases circulating adiponectin in patients with type 2 diabetes," <i>Blood Coagulation and Fibrinolysis</i> , 16(6):423-8 (2005)
	A115	Pietraszek, M. H. et al., "Blood serotonergic mechanisms in type 2 (non-insulin dependant) diabetes mellitus," <i>Thrombosis Research</i> , 66:765-74 (1992)
	A116	Prosser, W. A. et al., "Selective serotonin 5HT _{2A} inverse agonists promote sleep consolidation in male Wistar rats during the normal inactive phase," Poster #29

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-034US1	Application No. 10/540,650
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Bradley Teegarden, et al.	
		Filing Date April 21, 2006	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	A117	Satomura, K. et al., "Sarpogrelate, a specific 5HT ₂ -receptor antagonist, improves the coronary microcirculation in coronary artery disease," <i>Clinical Cardiology</i> , 25:28-32 (2002)
	A118	Sawnyok, J. et al., "Antidepressants as analgesics: an overview of central and peripheral mechanisms of action," <i>Journal of Psychiatry and Neuroscience</i> , 26(1):21-9 (2001)
	A119	Sharpley, A.L. et al., "Slow wave sleep in humans: role of 5HT _{2A} and 5HT _{2C} receptors," <i>Neuropharmacology</i> , 33(3/4):467-71 (1994)
	A120	Shibata, R. et al., "Adiponectin protects against myocardial ischemiareperfusion injury through AMPK- and COX-2- dependent mechanisms," <i>Nature Medicine</i> , advanced online Publication:1-8
	A121	Smith, G. et al., "Test-retest variability of serotonin 5HT _{2A} receptor binding measured with positron emission tomography and [¹⁸ F]altanserin in the human brain," <i>Synapse</i> , 30:380-92 (1998)
	A122	Staley, J. et al., "Comparison of [¹⁸ F]altanserin and [¹⁸ F]deutoaltanserin for PET imaging of serotonin _{2A} receptors in baboon brain: pharmacological studies," <i>Nuclear Medicine and Biology</i> , 28:271-9 (2001)
	A123	Strah-Pleyne, S. et al., "Discovery and SAR of novel 5HT _{2A} inverse-agonists," 227 th ACS National Meeting, MEDI 270 (2004)
	A124	Strah-Pleyne, S. et al., "Bioisosteric Modifications of Urea Derivatives as 5-HT _{2A} Inverse-Agonist", 229 th ACS National Meeting, MEDI 49 (2005)
	A125	Street, J. et al., "Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities," <i>Archives of General Psychiatry</i> , 57:968-76 (2000)
	A126	Takahashi, T. et al., "Sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, reduces albuminuria in patients with early-stage diabetic nephropathy," <i>Diabetes Research and Clinical Practice</i> , 58:123-9 (2002)
	A127	Takenaka, H. et al., "The effect of Anplag® (sarpogrelate HCL). Novel selective 5-HT ₂ antagonist of intraocular pressure in glaucoma patients," <i>Investigative Ophthalmology & Visual Science</i> , 36(4):S734 (1995) ABSTRACT
	A128	Talvik-Lofti, M. et al., "High HT _{2A} occupancy in M100907-treated schizophrenic patients," <i>Psychopharmacology</i> , 148:400-3 (2000)
	A129	Verstraete, M. "Prevention of atherosclerotic complications: controlled trial of ketanserin," <i>British Medical Journal</i> , 298:424-30 (1989)
	A130	Vikenes, K. et al., "Serotonin is associated with coronary artery disease and cardiac events," <i>Circulation</i> , 100:483-9 (1999)
	A131	Wilson, H et al., "LY53857, a HT ₂ receptor antagonist delays occlusion and inhibits platelet aggression in a rabbit model of carotid artery occlusion," <i>Thrombosis and Haemostasis</i> , 66 (3) 355-60 (1991)
	A132	Winokur, A. et al., "Acute effects of Mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study," <i>Biological Psychiatry</i> , 48:75-8 (2000)
	A133	Zhu, G. et al., "Synthesis and mode of action of [¹²⁵ I]- and [³ H]-labeled thieno[2,3,-c]pyridine antagonists of cell adhesion molecule expression," <i>Journal of Organic Chemistry</i> , 67:943-8 (2002)
	A134	Copy of International Search Report for International Application No. PCT/US2005/041726 dated May 18, 2006 by Authorized Officer Stefan Härtinger.
	A135	Copy of International Preliminary Report on Patentability for International Application No. PCT/US2005/041726 dated September 21, 2006 by Authorized Officer Stefan Härtinger.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-034US1	Application No. 10/540,650
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Bradley Teegarden, et al.	
		Filing Date April 21, 2006	Group Art Unit

*Not enclosed, available upon request

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	